<DOC>
	<DOCNO>NCT01829347</DOCNO>
	<brief_summary>The purpose study determine treatment ELAD System safe effective subject severe acute alcoholic hepatitis Lille score failure ( Lille score &gt; 0.45 ) .</brief_summary>
	<brief_title>Study Assess Safety Efficacy ELAD Subjects With Severe Acute Alcoholic Hepatitis ( sAAH ) Lille Score Failure</brief_title>
	<detailed_description>The Lille score use identify subject increase risk mortality ( Lille score failure ) . The Lille score prognostic model combine six reproducible variable Day 0 Day 7 steroid treatment . The Lille score use protocol use independent steroid administration 7 day evaluation . A Lille score &gt; 0.45 ( Lille score failure ) indicate subject substantially increase risk 30- 90-day mortality . Subjects severe acute alcoholic hepatitis ( sAAH ) often treated steroid soon diagnosis confirm . This study ass treatment ELAD System subject fail per Lille criterion , independent steroid administration . ELAD treatment do continuously 10 day addition standard care treatment . The Control group ( randomize receive ELAD treatment ) also get standard care treatment . Standard care define usual care diet , medication , treatment complication may arise , etc . sAAH patient .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Alcoholic</mesh_term>
	<criteria>Age ≥18 ; Total bilirubin ≥8 mg/dL ; Medical history alcohol abuse evidence causal temporal ( &lt; 6 week ) relationship use alcohol hospital admission episode sAAH ; Maddrey score ≥32 A clinical diagnosis severe acute alcoholic hepatitis ( sAAH ) ; Subject must liver biopsy investigator 's opinion , risk great perform liver biopsy , clinical diagnosis sufficient ; Subject must Lille score failure ( Lille score &gt; 0.45 ) define study . Platelet count &lt; 50,000/mm3 ; International Normalization Ratio ( INR ) &gt; 3.0 ; MELD score &gt; 35 ; Evidence infection unresponsive antibiotic ; Evidence jaundice &gt; 3 month ; Hospital admission episodes liver decompensation relate sAAH , ( episode sAAH ) within past 2 month ; Evidence hemodynamic instability ; Evidence active bleeding major hemorrhage define require ≥2 unit pack red blood cell maintain stable hemoglobin occur within 48 hour Screening ; Evidence occlusive portal vein thrombosis impair hepatopetal flow , evidence bile duct obstruction ; Evidence physical exam , history , laboratory evaluation significant concomitant disease expect life expectancy le 3 month ; Clinical evidence liver size reduction due cirrhosis , unless Investigator interpretation clinical evidence indicate liver size &lt; 10 cm volume &lt; 750 cc consider reduced individual subject ; Chronic endstage renal disease require chronic hemodialysis 8 week ( classified hepatorenal syndrome ) ; Uncontrolled seizure ; Positive serologies viral hepatitis B C ; Pregnancy determine βhuman chorionic gonadotropin ( HCG ) result ; Participation another investigational drug , biologic , device study within one month enrollment , except observational study ( observational study set affect safety and/or efficacy VTI210 clinical trial ) ; Currently list schedule liver transplant 90day study period ; Previous liver transplant ; Previous participation clinical trial involve ELAD ; Has Do Not Resuscitate Do Not Intubate ( DNR/DNI ) directive ( local equivalent ) Advanced Directive limit Standard Care place ( DNR/DNI criterion applicable UK ) ; Refusal participate VTI210E followup study ; Is unable provide address followup home visit . And inclusion/exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>liver failure</keyword>
	<keyword>acute alcoholic hepatitis</keyword>
	<keyword>patient fail steroid therapy</keyword>
	<keyword>alcoholic hepatitis</keyword>
	<keyword>steroid failure</keyword>
	<keyword>Lille criterion</keyword>
	<keyword>ELAD</keyword>
</DOC>